Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics. Its ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. It has preclinical programs in hemophilia A and Lysergic acid diethylamide and research stage programs in monogenic diseases, including certain central nervous system disorders and cancer immunotherapy.
Company Details
- Founded
- -
- Address
- Richmond, California
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Keywords
- IT Consulting.
- HQ
- Richmond, California
Sangamo Biosciences, Inc. Questions
Sangamo Biosciences, Inc.'s LinkedIn profile is https://www.linkedin.com/company/sangamo-biosciences-inc.
Sangamo Biosciences, Inc.'s industry is
Pharmaceutical Manufacturing
Sangamo Biosciences, Inc.'s top competitors are
Moderna,
Sangamo Therapeutics, Inc.,
Innoskel,
B. Braun Medical Inc. (Us),
Max'sens Conseil,
Monolith,
Therionic,
Sangamo Therapeutics France,
Actionsite,
Helio Nature.
Sangamo Biosciences, Inc.'s categories are Pharmaceutical Manufacturing
Sangamo Biosciences, Inc.'s founding year is 1995
